E-merge Capital Partners

Managing Partners Brad Klos and John M. Xitco lead all investment decisions. Klos is a serial medical device operator and inventor who previously served as CEO of Boa Medical, Traverse Vascular, and SinglePass Transseptal — all of which were acquired by strategic buyers between 2022 and 2025. Xitco brings cross-sector capital allocation experience and serves as a co-founder and key investor in the firm's incubated portfolio companies. Venture Partner Randy Werneth, an inventor on more than 70 U.S. patents, contributes deal sourcing and technical due diligence.

E-merge operates a dedicated venture fund — E-merge Fund I — that makes direct equity investments in early-stage medical device companies. The firm does not invest as a limited partner in other venture funds. Its capital is deployed primarily at the seed and Series A stages, with follow-on capacity for later-stage rounds.

Evolve Medtech Partners is a medical device incubator and development company where E-merge Managing Partner Brad Klos serves as Managing Partner, and Venture Partner Randy Werneth is a Partner. The two entities share leadership, deal flow, and technical resources. Evolve incubates device concepts from concept through early development; E-merge provides venture funding at the point those companies are ready to scale toward regulatory submission and commercial launch. This structure creates a proprietary sourcing funnel for E-merge.

E-merge focuses on interventional cardiology, vascular surgery, neurovascular access, and cardiac electrophysiology. Portfolio companies develop catheter-based technologies, percutaneous devices, venous stenting tools, and related interventional platform technologies. The firm targets Class II and III medical devices where product development risk is high and operating expertise is essential to navigating FDA clearance and initial clinical adoption.

As of mid-2025, the E-merge team has recorded three disclosed exits from companies the principals co-founded or incubated: Traverse Vascular (acquired June 2022), SinglePass Transseptal (acquired December 2023), and Boa Medical (acquired April 2025). Each of these exits preceded or occurred during the deployment of E-merge Fund I and was led by strategic acquirers in the medical device sector.

E-merge has disclosed that its advisory network includes relationship partners at firms such as DLA Piper and specialized healthcare lenders, but the firm has not publicly stated a policy on co-investing alongside other venture firms. Its primary model is to lead or co-lead rounds directly, often through its affiliated incubator funnel, rather than syndicating passively with external GPs.

E-merge invests in companies with R&D and commercial operations in the United States and the United Kingdom. Its medical advisory board includes practicing clinicians at major U.S. academic medical centers — including Emory Healthcare, Northwestern University Medical Center, and Advent Health Florida — as well as Guy's & St. Thomas' NHS Trust in London, reflecting an operational footprint in both the U.S. and European medical device markets.